Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Brexpiprazole is a prescription atypical antipsychotic. It is approved as adjunctive treatment with antidepressants for major depressive disorder in adults, for schizophrenia in adults and patients age 13 and older, and for agitation associated with dementia due to Alzheimer disease. Tablets are taken once daily with or without food.
read more about brexpiprazole ...The exact therapeutic mechanism of brexpiprazole is unknown. Its activity is thought to involve partial agonism at dopamine D2 and serotonin 5-HT1A receptors together with antagonism at serotonin 5-HT2A receptors. Brexpiprazole also interacts with other dopamine, serotonin, and adrenergic receptors, which contributes to its pharmacologic profile.
Brexpiprazole is used with an antidepressant for major depressive disorder in adults, as treatment for schizophrenia in adults and adolescents age 13 and older, and for agitation associated with dementia due to Alzheimer disease. It is not indicated as an as-needed treatment for Alzheimer-related agitation.
For adult major depressive disorder, treatment starts at 0.5 mg or 1 mg once daily and targets 2 mg daily, with a 3 mg maximum. Adult schizophrenia starts at 1 mg daily and targets 2 mg to 4 mg daily. Alzheimer-related agitation starts at 0.5 mg daily and increases to a 2 mg target dose.
Brexpiprazole carries boxed warnings for increased mortality in elderly patients with dementia-related psychosis and suicidal thoughts and behaviors with antidepressant treatment in younger people. Other risks include neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, compulsive behaviors, low blood pressure, falls, low white blood cell counts, seizures, and swallowing difficulty.
Yes. Brexpiprazole is an atypical antipsychotic with activity at dopamine, serotonin, and adrenergic receptors.
Brexpiprazole is taken once daily with or without food.
Yes. Current labeling includes schizophrenia treatment in patients age 13 and older.
No. Current labeling states that it is not indicated as an as-needed treatment for agitation associated with dementia due to Alzheimer disease.
Brexpiprazole. MedlinePlus. https://medlineplus.gov/druginfo/meds/a615046.html. Date Accessed September 16, 2026.
DailyMed - REXULTI (brexpiprazole) tablet. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6991c065-0f6e-433a-8f4f-796e0ece327f. Date Accessed September 16, 2026.
DailyMed - REXULTI (brexpiprazole) tablet and kit. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850. Date Accessed September 16, 2026.
FDALabel - REXULTI (brexpiprazole). https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/391046. Date Accessed September 16, 2026.
REXULTI (brexpiprazole) Tablets. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205422. Date Accessed September 16, 2026.